Navigation Links
Drug May Help Colitis Patients Avoid Surgery
Date:10/2/2009

Infliximab linked to fewer colectomies in study patients

FRIDAY, Oct. 2 (HealthDay News) -- Treatment with the drug infliximab (Remicade) reduced the need for surgery in ulcerative colitis patients by almost half, a new study found.

Ulcerative colitis causes chronic inflammation of the colon and often leads to surgical removal of the colon (colectomy).

This study included 728 patients who received either an inactive placebo or infliximab for 46 weeks. After one year of follow-up, the researchers found that "treatment with infliximab reduced the need for colectomy by 41 percent compared to patients treated with placebo," lead author and Mayo Clinic gastroenterologist Dr. William Sandborn, said in a Mayo Clinic news release.

The study appears in the October issue of the journal Gastroenterology.

"One of the most feared outcomes for ulcerative colitis patients is surgical removal of the colon. Our research hopes to provide other treatment solutions for patients beyond surgery," Sandborn said.

He provided consulting services for drug maker Centocor during this research. The Mayo Clinic was paid for Sandborn's services.

More information

The U.S. National Institute of Diabetes and Digestive and Kidney Diseases has more about ulcerative colitis.



-- Robert Preidt



SOURCE: Mayo Clinic, news release, Sept. 30, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Mouse Study Gives Clues to Colitis
2. New therapeutic targets in the treatment of ulcerative colitis
3. Narrow band imaging colonoscopy identifies flat dysplastic lesions in ulcerative colitis patients
4. Nationwide Survey Reveals Differing Physician and Patient Perceptions Regarding Impact of Ulcerative Colitis on Patients Lives
5. Although Remicade and Humira Are Being Increasingly Prescribed for Crohns Disease and Ulcerative Colitis, Insurers Are Subjecting Both Drugs to Multiple Cost-Control Strategies
6. Shire Launches Patient Education Forums on Better Managing the Challenges of Ulcerative Colitis
7. Medical Futures signs North American licensing rights to New Biologic agent for Ulcerative Colitis
8. A rare case of ischemic colitis caused by chronic venous insufficiency
9. Study underway to find an alternative cure for Crohns disease and ulcerative colitis
10. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
11. Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... Little Rock, AR (PRWEB) , ... February 11, 2016 , ... ... Change in their community by announcing a new fundraiser in support of a local ... agency also hopes the campaign will bring awareness to, and rally support for, all ...
(Date:2/11/2016)... Alexandria, VA (PRWEB) , ... February 11, 2016 , ... ... of its new office in the heart of Old Town at 108 South Columbus ... individuals and businesses the highest level of medical care in the convenience of their ...
(Date:2/11/2016)... ... , ... Husted Kicking has completed its Third Annual Husted Kicking ... 7th, 2016 according to kicking coach Michael Husted. , “This event serves as an ... in Indianapolis,” says Husted. “The NFL uses a third party organization to select players ...
(Date:2/11/2016)... ... February 11, 2016 , ... Research led ... rates of several common cancer screenings, especially among women. Cancer screenings are often ... rates. , The study,“What Does Medicaid Expansion Mean for Cancer Screening and ...
(Date:2/10/2016)... ... February 10, 2016 , ... The 9th ... Molecular Imaging Congress (WMIC), will be held in New York City, NY on ... Biology…Improving Therapy.” The congress will highlight and emphasize how imaging reveals a greater ...
Breaking Medicine News(10 mins):
(Date:2/11/2016)... , Feb. 11, 2016  Proliant Biologicals is proud ... Serum Albumin (BSA) manufacturing facility.  The facility is located ... , in Feilding. Boone ... to functionally duplicate the systems in the U.S. facility, ... used for U.S. installations.  --> ...
(Date:2/11/2016)... Breast Cancer Therapeutics in Asia-Pacific Markets to 2021 ... breast cancer market will experience considerable expansion from $1.9 billion ... Annual Growth Rate (CAGR) of 8.5%. --> Breast ... that the Asia-Pacific (APAC) breast cancer ... to $3.4 billion by 2021, at a Compound Annual Growth ...
(Date:2/11/2016)... , Feb. 11, 2016  AbbVie, a ... AbbVie Rheumatology Scholarship, designed to provide financial support ... as they pursue higher education goals. Fifteen scholars ... the 2016-2017 school year. The AbbVie Rheumatology Scholarship ... Haas , vice president, corporate social responsibility, brand ...
Breaking Medicine Technology: